HOWARU® Protect Early Life HOWARU® Protect Early Life Demand is growing for safe products with proven efficacy to support the immune health of infants. As part of the IFF Health premium ingredient range, HOWARU® Protect Early Life contains the probiotic strain HOWARU® L. rhamnosus HN001™ and is designed specifically for pregnant women and children (0 to 2 years)*. It is proven to safely support the development of immune health in infants and children. Download the handout to learn more. Download PDF Product Information: Ingredients: HOWARU® Lacticaseibacillus rhamnosus HN001™ CFU: 6B CFU | HOWARU® Lacticaseibacillus rhamnosus HN001™ Health Benefits: Early Life DevelopmentImmune ADVANTAGES Advantages of HOWARU® Protect Early Life Supports immune health to help build infant’s natural defenses and continually supports immune health into childhood Provides increased levels of healthy bacteria in the intestinal tract of infants SUPPORT THE DEVELOPMENT OF IMMUNE HEALTH IN YOUNG CHILDREN A double-blind, randomized placebo-controlled clinical study was designed to test the efficacy of HOWARU® L. rhamnosus HN001™ on the prevalence of eczema and allergic sensitization. In total, 316 mothers and their infants were divided into placebo and HN001™ groups. Pregnant mothers were supplemented daily from 5 weeks pre-term to 6 months post-term if breastfeeding. Infants were supplemented daily from birth until 2 years old. The probiotic was administered in capsules to mothers and as powder, powder diluted in milk or sprinkled on top of the food to infants. At the age-points of 2, 4, 6 and 11 years, allergic disease-related outcomes (e.g., atopic sensitization) were determined by using clinical diagnosis and skin prick tests1-5. Children in the HN001™ group had reduced allergic sensitization compared to placebo, which became statistically significant in the first 6 years of life and persisted through 11 years. References: 1. Wickens et al., 2008; 2. Wickens et al., 2012; 3. Wickens et al., 2013; 4. Wickens et al. 2018a; 5. Wickens et al. 2018b.